As of September 18, 2026, Medanta's stock is trading above key moving averages across daily, weekly, and monthly timeframes, indicating a generally positive technical stance. The daily and weekly charts show prices above their respective Supertrend indicators, supporting a bullish trend on these shorter-term periods. However, the monthly timeframe shows the price below its Supertrend, suggesting a potential conflict or a longer-term consolidation phase.

On the daily chart, the price is above the 20-day Exponential Moving Average (EMA) (1441.47) and the 50-day EMA (1406.22), with positive slopes on the SMAs. The weekly chart also shows prices above the 20-day EMA (1356.44) and 50-day EMA (1272.9), with strong upward slopes on the SMAs, reinforcing bullish momentum in the medium term. The monthly chart shows the price above the 20-day EMA (1240.54), but the overall trend direction is indicated as bearish by the monthly Supertrend.

Nearest support is observed around ₹1474.23 (1.68% below the current price), followed by ₹1456.27 (2.88% below). Resistance is noted at ₹1544.0, approximately 2.97% above the current price. The stock has experienced an extreme upward gap of 5% on September 18, 2026, with a Z-score of 4.01. Recent market activity shows 3 positive attention events in the last 30 days, with no downside or neutral events.

The stock's risk profile includes an annualized volatility of 32% and an Average True Range (ATR) of 3.28%. The current drawdown is minimal at -1%, while the maximum drawdown observed was -33%. The stock is positioned at the higher end of its recent trading ranges, with its position in the 20-day range at 73% and in the 252-day range at 92%.

Global Health Limited (Medanta) held its 22nd Annual General Meeting on September 16, 2026. During the meeting, shareholders approved the audited financial statements for the fiscal year ending March 31, 2026, and declared a final dividend of ₹0.50 per equity share. The re-election of Mr. Pankaj Sahni as a director and the remuneration for cost auditors for the 2026-27 financial year were also approved. Voting results, confirmed by a scrutinizer's report dated September 16, 2026, showed overwhelming support for these resolutions, with the dividend resolution passing with 99.9997% of valid votes in favour. Separately, the company's management is scheduled to engage with institutional investors. On September 17, 2026, management attended the Jefferies India Forum 2026, and on September 18, 2026, they participated in the Kotak Healthcare Forum 2026. Additionally, a one-on-one meeting with USS Investment Management Ltd is planned for September 23, 2026. No unpublished price-sensitive information is expected to be shared in these investor interactions.

As of September 18, 2026, Global Health, trading under the symbol MEDANTA on the NSE, has seen its stock price increase to ₹1499.4 from a previous price of ₹1424.0. This represents a recent upward movement in the stock's valuation. The company's profile and exchange listing remain consistent with prior context.

Global Health Limited (Medanta) has recently disclosed its participation in several investor and analyst meetings. These engagements, scheduled between September 14 and September 23, 2026, involve meetings with entities such as USS Investment Management Ltd, Polar Capital, and Chikara Investments, as well as participation in the Jefferies India Forum 2026 and Kotak Healthcare Forum 2026. The company has explicitly stated that no unpublished price-sensitive information will be shared during these interactions. Additionally, the company held its 22nd Annual General Meeting on September 16, 2026. During this meeting, shareholders approved the audited financial statements for the fiscal year ending March 31, 2026, and a final dividend of ₹0.50 per equity share. Mr. Pankaj Sahni was re-elected as a director, and the remuneration for cost auditors for the 2026-27 financial year was also approved. The voting results for these resolutions, conducted via remote e-voting and during the meeting, showed strong approval percentages, with the dividend resolution receiving 99.9997% of valid votes in favour.

Global Health, trading on the NSE, has shown a consistent upward trend in its revenue from operations over the reported periods. Revenue grew from ₹1,121.05 crore in Q3 FY2025-26 to ₹1,304.05 crore in Q1 FY2026-27. This revenue growth has been accompanied by an increase in profit before tax, which rose from ₹119.78 crore in Q3 FY2025-26 to ₹213.26 crore in Q1 FY2026-27. The profit for the period also saw an increase, moving from ₹95.03 crore in Q3 FY2025-26 to ₹157.25 crore in Q1 FY2026-27. The company's expenses have also risen, but at a pace that has allowed for improved profitability. Tax expense has followed a similar upward trajectory as profits. Comprehensive income for the period has also shown growth, from ₹95.65 crore in Q3 FY2025-26 to ₹152.09 crore in Q1 FY2026-27.

The company's stock shows several technical indicators suggesting a constructive market setup. On a daily timeframe, the closing price of ₹1499.4 is above both the 20-day Exponential Moving Average (EMA) of ₹1441.47 and the 50-day EMA of ₹1406.22. The Supertrend indicator is also 'bullish' at ₹1370.58, indicating upward momentum. Weekly trends reinforce this, with the closing price exceeding the 20-day EMA (₹1356.44) and 50-day EMA (₹1272.9), and the Supertrend signal being 'bullish' at ₹1215.36. The stock has also demonstrated positive returns across various periods, notably a 44% return over the last six months and a 26% year-to-date return.

The company's monthly trend indicators suggest a cautionary outlook, with the Supertrend indicator at ₹1559.82 indicating a bearish signal on a monthly timeframe. While daily and weekly trends show bullish Supertrend signals, the monthly perspective warrants attention. The stock has experienced a maximum drawdown of -33% historically, and its current annualized volatility stands at 32%.